JPWO2019232433A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019232433A5 JPWO2019232433A5 JP2020566958A JP2020566958A JPWO2019232433A5 JP WO2019232433 A5 JPWO2019232433 A5 JP WO2019232433A5 JP 2020566958 A JP2020566958 A JP 2020566958A JP 2020566958 A JP2020566958 A JP 2020566958A JP WO2019232433 A5 JPWO2019232433 A5 JP WO2019232433A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- neoantigen
- composition
- pharmaceutically acceptable
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 14
- 206010028980 Neoplasm Diseases 0.000 claims 13
- 229940125904 compound 1 Drugs 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 9
- 229960005486 vaccine Drugs 0.000 claims 7
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 6
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 6
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 6
- 230000001613 neoplastic effect Effects 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 3
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 3
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 3
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 3
- 206010025323 Lymphomas Diseases 0.000 claims 3
- 208000034578 Multiple myelomas Diseases 0.000 claims 3
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 3
- 206010060862 Prostate cancer Diseases 0.000 claims 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 3
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 3
- 210000003719 b-lymphocyte Anatomy 0.000 claims 3
- 208000029742 colonic neoplasm Diseases 0.000 claims 3
- 201000004101 esophageal cancer Diseases 0.000 claims 3
- 206010017758 gastric cancer Diseases 0.000 claims 3
- 230000001939 inductive effect Effects 0.000 claims 3
- 208000032839 leukemia Diseases 0.000 claims 3
- 201000005202 lung cancer Diseases 0.000 claims 3
- 208000020816 lung neoplasm Diseases 0.000 claims 3
- 230000036210 malignancy Effects 0.000 claims 3
- 201000001441 melanoma Diseases 0.000 claims 3
- 201000000050 myeloid neoplasm Diseases 0.000 claims 3
- 210000001672 ovary Anatomy 0.000 claims 3
- 210000001581 salivary duct Anatomy 0.000 claims 3
- 201000011549 stomach cancer Diseases 0.000 claims 3
- 206010046766 uterine cancer Diseases 0.000 claims 3
- 101150013553 CD40 gene Proteins 0.000 claims 2
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims 2
- -1 PD1 Proteins 0.000 claims 2
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 239000011230 binding agent Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 210000005170 neoplastic cell Anatomy 0.000 claims 2
- 239000012275 CTLA-4 inhibitor Substances 0.000 claims 1
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 1
- 102000019034 Chemokines Human genes 0.000 claims 1
- 108010012236 Chemokines Proteins 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 1
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims 1
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims 1
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 102000017578 LAG3 Human genes 0.000 claims 1
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 claims 1
- 108010058846 Ovalbumin Proteins 0.000 claims 1
- 241000237988 Patellidae Species 0.000 claims 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 1
- 108010071390 Serum Albumin Proteins 0.000 claims 1
- 102000007562 Serum Albumin Human genes 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000002238 attenuated effect Effects 0.000 claims 1
- 208000035269 cancer or benign tumor Diseases 0.000 claims 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 238000012606 in vitro cell culture Methods 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 229960005386 ipilimumab Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 229940092253 ovalbumin Drugs 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862679699P | 2018-06-01 | 2018-06-01 | |
| US201862679696P | 2018-06-01 | 2018-06-01 | |
| US62/679,699 | 2018-06-01 | ||
| US62/679,696 | 2018-06-01 | ||
| PCT/US2019/034992 WO2019232433A2 (en) | 2018-06-01 | 2019-05-31 | Methods of using splicing modulators |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021525765A JP2021525765A (ja) | 2021-09-27 |
| JP2021525765A5 JP2021525765A5 (https=) | 2022-06-06 |
| JPWO2019232433A5 true JPWO2019232433A5 (https=) | 2022-06-06 |
| JP7346466B2 JP7346466B2 (ja) | 2023-09-19 |
Family
ID=67070907
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020566958A Active JP7346466B2 (ja) | 2018-06-01 | 2019-05-31 | スプライシング調節薬の使用方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11998544B2 (https=) |
| EP (1) | EP3801523B1 (https=) |
| JP (1) | JP7346466B2 (https=) |
| KR (1) | KR20210016406A (https=) |
| CN (1) | CN112367996B (https=) |
| AU (1) | AU2019279012A1 (https=) |
| BR (1) | BR112020024551A2 (https=) |
| CA (1) | CA3101205A1 (https=) |
| IL (2) | IL278740B2 (https=) |
| MX (1) | MX2020012940A (https=) |
| WO (1) | WO2019232433A2 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019199667A2 (en) * | 2018-04-09 | 2019-10-17 | Keaney Gregg F | Certain pladienolide compounds and methods of use |
| JOP20200268A1 (ar) | 2018-06-01 | 2020-10-26 | Eisai R&D Man Co Ltd | تضفير مترافقات عقار جسم مضاد معدل وطرق استخدامها |
| MX2020012940A (es) | 2018-06-01 | 2021-03-25 | Eisai R&D Man Co Ltd | Metodos de uso de moduladores de empalme. |
| PE20211473A1 (es) | 2018-12-13 | 2021-08-05 | Eisai Randd Man Co Ltd | Conjugados de anticuerpo-farmaco de herboxidieno y metodos de uso |
| EP4149483A4 (en) * | 2020-05-15 | 2024-09-11 | Fred Hutchinson Cancer Center | COMPOSITIONS AND METHODS FOR IMPROVING CANCER IMMUNOTHERAPY |
| AR122546A1 (es) | 2020-06-05 | 2022-09-21 | Eisai R&D Man Co Ltd | Conjugados de anticuerpo anti bcma-fármaco y métodos de uso |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0368684B2 (en) | 1988-11-11 | 2004-09-29 | Medical Research Council | Cloning immunoglobulin variable domain sequences. |
| HU212924B (en) | 1989-05-25 | 1996-12-30 | Chiron Corp | Adjuvant formulation comprising a submicron oil droplet emulsion |
| US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| NZ322175A (en) | 1995-11-10 | 1999-02-25 | Elan Corp Plc | Peptides which enhance transport across tissues and methods of identifying the same |
| IL148079A0 (en) | 1999-08-24 | 2002-09-12 | Medarex Inc | Human ctla-4 antibodies and compositions containing the same |
| TWI311558B (en) | 2001-02-01 | 2009-07-01 | Mercian Corporatio | Novel physiologically active substance |
| TWI334866B (en) | 2002-05-29 | 2010-12-21 | Mercian Corp | Novel physiologically active substances |
| RU2338741C2 (ru) | 2002-07-31 | 2008-11-20 | Мершан Корпорейшн | Новые физиологически активные вещества |
| JP4459051B2 (ja) | 2002-07-31 | 2010-04-28 | メルシャン株式会社 | 新規生理活性物質 |
| JP4439401B2 (ja) | 2002-11-29 | 2010-03-24 | メルシャン株式会社 | マクロライド系化合物の製造方法 |
| EP1705247A4 (en) * | 2003-11-27 | 2008-08-20 | Mercian Corp | DNA ACCOMPANYING HYDROXYLATION OF A MAKROLIDE COMPOUND |
| CN1977046A (zh) | 2004-07-20 | 2007-06-06 | 卫材R&D管理有限公司 | 编码参与普拉地内酯生物合成的多肽的dna |
| RU2494107C2 (ru) * | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| CN101282967B (zh) * | 2005-10-13 | 2011-01-26 | 卫材R&D管理有限公司 | 普拉二烯内酯b和普拉二烯内酯d的全合成 |
| JPWO2008016187A1 (ja) * | 2006-08-02 | 2009-12-24 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | プラジエノライド類のターゲット分子、本ターゲット分子に結合する化合物、及びそのスクリーニング方法 |
| US20080312317A1 (en) | 2007-04-12 | 2008-12-18 | Eisai R&D Management Co., Ltd. | 12 membered-ring macrolactam derivatives |
| US9981046B2 (en) | 2012-05-15 | 2018-05-29 | Concortis Biosystems, Corp., a wholly owned Subsidiary of Sorrento Therapeutics, Inc. | Drug-conjugates, conjugation methods, and uses thereof |
| CN113967253A (zh) | 2012-05-15 | 2022-01-25 | 百时美施贵宝公司 | 通过破坏pd-1/pd-l1信号传输的免疫治疗 |
| KR20160093012A (ko) | 2013-11-05 | 2016-08-05 | 코그네이트 바이오서비시즈, 인코포레이티드 | 암 치료를 위한 체크포인트 억제제 및 치료제의 배합물 |
| UA119458C2 (uk) * | 2014-05-15 | 2019-06-25 | Ейсей Р Енд Д Менеджмент Ко., Лтд. | Сполуки піридину пладієноліду та способи застосування |
| ES2916923T3 (es) | 2014-07-11 | 2022-07-06 | Ventana Med Syst Inc | Anticuerpos anti-PD-L1 y usos diagnósticos de los mismos |
| ES2887201T3 (es) | 2015-09-01 | 2021-12-22 | Eisai R&D Man Co Ltd | Variantes de empalme asociadas con mutantes neomórficos de SF3B1 |
| RU2619208C2 (ru) | 2015-10-08 | 2017-05-12 | ДИАМОНДЗЛИТЕ ЛИМИТЕД Тридент Чамберс | Способ профилактического лечения при развитии неопластических процессов кожной ткани, таких как меланома, базально-клеточный рак, плоскоклеточный рак |
| SG11201803519YA (en) * | 2015-11-18 | 2018-06-28 | Eisai R&D Man Co Ltd | A solid state form of pladienolide pyridine compounds and methods of use |
| EP3423105B1 (en) | 2016-03-02 | 2021-05-05 | Eisai R&D Management Co., Ltd. | Eribulin-based antibody-drug conjugates and methods of use |
| WO2017214182A1 (en) * | 2016-06-07 | 2017-12-14 | The United States Of America. As Represented By The Secretary, Department Of Health & Human Services | Fully human antibody targeting pdi for cancer immunotherapy |
| US10669338B2 (en) * | 2016-06-17 | 2020-06-02 | Immunomedics, Inc. | Anti-PD-1 checkpoint inhibitor antibodies that block binding of PD-L1 to PD-1 |
| US10825015B2 (en) | 2018-03-07 | 2020-11-03 | Capital One Services, Llc | Secure payment using a network of wearable devices |
| MX2020012940A (es) | 2018-06-01 | 2021-03-25 | Eisai R&D Man Co Ltd | Metodos de uso de moduladores de empalme. |
| JOP20200268A1 (ar) | 2018-06-01 | 2020-10-26 | Eisai R&D Man Co Ltd | تضفير مترافقات عقار جسم مضاد معدل وطرق استخدامها |
| PE20211473A1 (es) | 2018-12-13 | 2021-08-05 | Eisai Randd Man Co Ltd | Conjugados de anticuerpo-farmaco de herboxidieno y metodos de uso |
| JP7657213B2 (ja) | 2019-11-07 | 2025-04-04 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 抗メソテリンエリブリン抗体－薬物コンジュゲート及び使用方法 |
| CN118949063A (zh) | 2020-01-22 | 2024-11-15 | 上海森辉医药有限公司 | 艾日布林衍生物的药物偶联物、其制备方法及其在医药上的应用 |
| AR122546A1 (es) | 2020-06-05 | 2022-09-21 | Eisai R&D Man Co Ltd | Conjugados de anticuerpo anti bcma-fármaco y métodos de uso |
-
2019
- 2019-05-31 MX MX2020012940A patent/MX2020012940A/es unknown
- 2019-05-31 KR KR1020207037344A patent/KR20210016406A/ko not_active Ceased
- 2019-05-31 JP JP2020566958A patent/JP7346466B2/ja active Active
- 2019-05-31 US US17/059,876 patent/US11998544B2/en active Active
- 2019-05-31 CN CN201980042241.3A patent/CN112367996B/zh active Active
- 2019-05-31 EP EP19733906.2A patent/EP3801523B1/en active Active
- 2019-05-31 WO PCT/US2019/034992 patent/WO2019232433A2/en not_active Ceased
- 2019-05-31 IL IL278740A patent/IL278740B2/en unknown
- 2019-05-31 IL IL305047A patent/IL305047A/en unknown
- 2019-05-31 AU AU2019279012A patent/AU2019279012A1/en not_active Abandoned
- 2019-05-31 CA CA3101205A patent/CA3101205A1/en active Pending
- 2019-05-31 BR BR112020024551-8A patent/BR112020024551A2/pt unknown
-
2024
- 2024-04-25 US US18/645,759 patent/US20240350484A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021525765A5 (https=) | ||
| KR102349056B1 (ko) | Pd-1 억제제를 투여함으로써 피부암을 치료하는 방법 | |
| JP2022078265A (ja) | 肺癌の処置のための抗ｐｄ－１抗体 | |
| JP2022532490A (ja) | 癌の治療における有効性の増強のためのｐｄ－１阻害剤とｌａｇ－３阻害剤の組み合わせ | |
| JP2020534250A5 (https=) | ||
| JP2020516240A5 (https=) | ||
| JP2018509175A (ja) | 二重特異性四価抗体並びにその製作及び使用方法 | |
| JP2016509582A5 (https=) | ||
| WO2020238926A1 (en) | Anti-b7-h3 antibodies | |
| US20230279105A1 (en) | Anti-tim-3 antibodies | |
| JPWO2019157332A5 (https=) | ||
| Pan et al. | Characterization of a novel bispecific antibody targeting tissue factor-positive tumors with T cell engagement | |
| US20220259313A1 (en) | Administration of a pd-1 inhibitor for for treating skin cancer | |
| EP3827021A1 (en) | Antibodies targeting a complex comprising non-classical hla-i and neoantigen and their methods of use | |
| JP2022523804A (ja) | がんの処置における増強された有効性のためのｉｌ－４／ｉｌ－１３経路阻害剤 | |
| JPWO2019232433A5 (https=) | ||
| JPWO2019246356A5 (https=) | ||
| ES2980363T3 (es) | Administración intralesional de inhibidores de PD-1 para el tratamiento del cáncer de piel | |
| CN113316449A (zh) | 胍那苄作为免疫疗法的佐剂 | |
| Luiten et al. | Chimeric bispecific OC/TR monoclonal antibody mediates lysis of tumor cells expressing the folate-binding protein (MOv18) and displays decreased immunogenicity in patients | |
| KR20250155054A (ko) | 흑색종 치료에서의 효능 강화를 위한 pd-1 억제제와 lag-3 억제제의 병용 | |
| US20200148758A1 (en) | Therapeutic combinations comprising eosinophil-depleting antibodies and uses thereof | |
| JPWO2023016348A5 (https=) | ||
| RU2020143065A (ru) | Способы применения модуляторов сплайсинга | |
| JPWO2021055350A5 (https=) |